Orbis Medicines signs cardiometabolic drug discovery deal with Novo Nordisk worth up to USD 1.4 billion

NVO•2026-09-17

Orbis Medicines and Novo Nordisk announce multi-target discovery partnership

Orbis Medicines signed a multi-target drug discovery partnership with Novo Nordisk valued at up to USD 1.4 billion.

Deal terms include an upfront payment, development milestones, commercial milestones, tiered royalties, and a strategic Novo investment in Orbis.

The collaboration targets orally bioavailable macrocycle therapeutics for cardiometabolic diseases using Orbis’ AI-enabled macrocycle discovery platform.

Sources

Orbis Medicines signs cardiometabolic drug discovery deal with Novo Nordisk worth up to USD 1.4 billion

Publicnow

Orbis Medicines signs cardiometabolic drug discovery deal with Novo Nordisk worth up to USD 1.4 billion

Orbis Medicines and Novo Nordisk announce multi-target discovery partnership

Related News

Apollo explores sale options for floating LNG infrastructure operator Energos, sources say

Amer Sports Chief Strategy Officer Chen Wen-Chang reports $3,123,782 disposal of common shares

Comstock Resources, Inc. <CRK.N>: Truist Securities initiates coverage with Hold rating; target price $16

Sources

Orbis Medicines signs cardiometabolic drug discovery deal with Novo Nordisk worth up to USD 1.4 billion

DarioHealth wins contract with New Jersey health plan covering 1.5 million lives

CoreWeave signs 3- to 6-month compute contracts priced at about $40 million per megawatt annualized